{"pub": "marketwatch", "url": "https://marketwatch.com/articles/novartis-stock-fda-gene-therapy-trial-spinal-injection-zolgensma-51572441094", "downloaded_at": "2019-10-30 14:18:39.959359+00:00", "title": "Novartis Stock Is Falling After the FDA Puts a Partial Hold on a Gene-Therapy Trial", "language": "en", "text": "The Food and Drug Administration placed a partial hold on studies of an experimental version of the $2.1 million gene therapy Zolgensma, sending shares of the drug\u2019s maker, Novartis, down 1.3% in premarket trading.\n\nThe clinical hold, announced Wednesday morning by Novartis (ticker: NVS), suspends portions of a trial investigating the spinal injection of Novartis\u2019s gene therapy to treat spinal muscular atrophy, called AVXS-101. The marketed version of AVXS-101, Zolgensma, is administered intravenously.\n\n...", "description": "The clinical hold, announced Wednesday morning by Novartis suspends portions of a trial investigating the spinal injection of Novartis\u2019s gene therapy to treat spinal muscular atrophy.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DH027_Novart_OR_20191022085143.jpg", "published_at": "2019-10-30"}